Floatz logo

ds-8201a

Hormone Receptor Positive Breast Carcinoma

MedSIRantibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

116 Active assets in the Hormone Receptor Positive Breast Carcinoma cohort.

Asset / SponsorPhaseRating
Everolimus
Ellipses Pharma
Phase 4BBB
EXEMESTANE
Fujian Cancer Hospital
Phase 4BBB
Arimidex
University of Illinois at Chicago
Phase 4BBB
Ribociclib
BeOne Medicines
Phase 4BBB
Palbociclib
BeOne Medicines
Phase 3BBB

View all 50 →

Same molecule, other indications

ds-8201a is also rated in:

breast neoplasmDormant
BB
Indicative ·
64 / 100
View asset →
Residual Invasive Breast CancerDormant
B
Indicative ·
60 / 100
View asset →
HER2 positive breast carcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →